Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dihydroartemisinin-piperaquine (DHA-PPQ) is a promising new artemisinin combination treatment. There are no published data on the intentional use of the drug in pregnancy. Between June 2006 and January 2007, 50 Karen pregnant women with recurrent P. falciparum infections, despite 7-day treatments with quinine or artesunate (+/-clindamycin) or both, were treated with DHA-PPQ. This rescue treatment was effective and well tolerated and there was no evidence of toxicity for the mothers or the fetus. The PCR adjusted cure rate by Kaplan Meier analysis at day 63 was 92.2% (95% CI: 76.9-97.4).

Original publication




Journal article


The American journal of tropical medicine and hygiene

Publication Date





543 - 545


Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand.


Animals, Humans, Plasmodium falciparum, Plasmodium vivax, Pregnancy Complications, Infectious, Malaria, Falciparum, Fever, Artemisinins, Quinolines, Antimalarials, Drug Therapy, Combination, Retrospective Studies, Gravidity, Parity, Gestational Age, Pregnancy, Adolescent, Adult, Thailand, Female